{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:18:06Z","timestamp":1783477086020,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundamental Fund"},{"name":"Thailand Science Research and Innovation (TSRI), Thailand"},{"name":"Program Management Unit for Human Resources and Institutional Development, Research and Innovation (PMU-B)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are aggressive hematologic malignancies with limited targeted treatment options and poor clinical outcomes across all age groups. CD147 is a multifunctional transmembrane glycoprotein that is highly expressed in various cancers, including T-cell leukemia and lymphoma. Its involvement in tumor progression and immune evasion makes CD147 a promising target for cancer immunotherapy. Monoclonal antibody-based immunotherapy can eliminate tumor cells not only by blocking oncogenic signaling pathways but also by engaging immune effector cells through antibody-dependent cellular cytotoxicity (ADCC). Enhancing ADCC has therefore emerged as a crucial strategy to enhance the therapeutic efficacy of anti-cancer antibodies. This study aimed to evaluate the functional activity of a fully humanized Fc-engineered anti-CD147 monoclonal antibody, HuM6-1B9-5M, which was designed to enhance ADCC by introducing five Fc mutations (L235V\/F243L\/R292P\/Y300L\/P396L). HuM6-1B9-5M was successfully expressed in HEK293T cells and retained CD147 binding activity and specificity comparable to those of the parental antibody. Biolayer interferometry against CD147 confirmed that Fc substitutions did not adversely affect antigen-binding affinity. Functional assays using PBMC effector cells demonstrated enhanced ADCC activity of HuM6-1B9-5M relative to the wild-type antibody (HuM6-1B9-WT) against Jurkat and SupT1 cell lines, representing T-ALL and T-LBL models, respectively.<\/jats:p>","DOI":"10.1038\/s41598-026-52003-x","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:15:41Z","timestamp":1778249741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fc engineering of a fully humanized anti-CD147 monoclonal antibody enhances ADCC against T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Zaw Ye","family":"Htet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanathat","family":"Pamonsupornwichit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokporn","family":"Sornsuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsima","family":"Viriyaadhammaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phatcharida","family":"Jantaree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umpa","family":"Yasamut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutjeera","family":"Intasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatchai","family":"Tayapiwatana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"52003_CR1","doi-asserted-by":"publisher","first-page":"997482","DOI":"10.3389\/fimmu.2022.997482","volume":"13","author":"J Feng","year":"2022","unstructured":"Feng, J. et al. Treatment of aggressive T-cell lymphoma\/leukemia with anti-CD4 CAR T cells. Front. Immunol. 13, 997482 (2022).","journal-title":"Front. Immunol."},{"key":"52003_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/cancers15010094","volume":"15","author":"KKL Fang","year":"2022","unstructured":"Fang, K. K. L., Lee, J. B. & Zhang, L. Adoptive cell therapy for T-cell malignancies. Cancers 15, 94 (2022).","journal-title":"Cancers"},{"key":"52003_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","volume":"9","author":"N Maciocia","year":"2025","unstructured":"Maciocia, N., Wade, B. & Maciocia, P. CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? Blood Adv. 9, 913\u2013923 (2025).","journal-title":"Blood Adv."},{"key":"52003_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40164-022-00368-w","volume":"12","author":"D Caracciolo","year":"2023","unstructured":"Caracciolo, D. et al. The emerging scenario of immunotherapy for T-cell acute lymphoblastic leukemia: advances, challenges and future perspectives. Exp. Hematol. Oncol. 12, 5 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"52003_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.blre.2017.08.006","volume":"32","author":"E Vadillo","year":"2018","unstructured":"Vadillo, E., Dorantes-Acosta, E., Pelayo, R. & Schnoor, M. T cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood rev. 32, 36\u201351 (2018).","journal-title":"Blood rev."},{"key":"52003_CR6","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.3816\/CLM.2009.s.015","volume":"9","author":"D Hoelzer","year":"2009","unstructured":"Hoelzer, D. & G\u00f6kbuget, N. T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin. Lymphoma Myeloma. 9, S214\u2013S221 (2009).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"52003_CR7","first-page":"458","volume":"10","author":"UM Yildirim","year":"2023","unstructured":"Yildirim, U. M. et al. Acute complications observed during intensive chemotherapy in pediatric patients with acute lymphoblastic leukemia: single-center experience. North. Clin. Istanb. 10, 458 (2023).","journal-title":"North. Clin. Istanb"},{"key":"52003_CR8","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/cancers11111803","volume":"11","author":"A Landras","year":"2019","unstructured":"Landras, A. et al. CD147 is a promising target of tumor progression and a prognostic biomarker. Cancers 11, 1803 (2019).","journal-title":"Cancers"},{"key":"52003_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2559.2009.03280.x","volume":"54","author":"Y Li","year":"2009","unstructured":"Li, Y. et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 54, 677\u2013687 (2009).","journal-title":"Histopathology"},{"key":"52003_CR10","first-page":"157","volume":"7","author":"UH Weidle","year":"2010","unstructured":"Weidle, U. H., Scheuer, W., Eggle, D., Klostermann, S. & Stockinger, H. Cancer-related issues of CD147. Cancer genom proteom. 7, 157\u2013169 (2010).","journal-title":"Cancer genom proteom."},{"key":"52003_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/iub.11","volume":"60","author":"L Jia","year":"2008","unstructured":"Jia, L., Wang, H., Qu, S., Miao, X. & Zhang, J. CD147 regulates vascular endothelial growth factor-a expression, tumorigenicity, and chemosensitivity to curcumin in hepatocellular carcinoma. IUBMB life. 60, 57\u201363 (2008).","journal-title":"IUBMB life"},{"key":"52003_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0145-2126(00)00104-1","volume":"25","author":"O Kuittinen","year":"2001","unstructured":"Kuittinen, O., Savolainen, E. R., Koistinen, P., M\u00f6tt\u00f6nen, M. & Turpeenniemi-Hujanen, T. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk. Res. 25, 125\u2013131 (2001).","journal-title":"Leuk. Res."},{"key":"52003_CR13","doi-asserted-by":"publisher","first-page":"215762","DOI":"10.1016\/j.canlet.2022.215762","volume":"542","author":"NS Zheng","year":"2022","unstructured":"Zheng, N. S. et al. CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia. Cancer Lett. 542, 215762 (2022).","journal-title":"Cancer Lett."},{"key":"52003_CR14","doi-asserted-by":"publisher","first-page":"9178","DOI":"10.3390\/ijms25179178","volume":"25","author":"I Spinello","year":"2024","unstructured":"Spinello, I., Labbaye, C. & Saulle, E. Metabolic function and therapeutic potential of CD147 for hematological malignancies: an overview. Int. J. Mol. Sci. 25, 9178 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"52003_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/07357900701867892","volume":"26","author":"X Chen","year":"2008","unstructured":"Chen, X. et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell proliferation, activation, adhesion, and migration activity in the human Jurkat T-lymphoma cell line. Cancer Invest. 26, 689\u2013697 (2008).","journal-title":"Cancer Invest."},{"key":"52003_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12967-019-2024-y","volume":"17","author":"K Pahk","year":"2019","unstructured":"Pahk, K. et al. A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation. J. Transl Med. 17, 274 (2019).","journal-title":"J. Transl Med."},{"key":"52003_CR17","doi-asserted-by":"publisher","first-page":"9429","DOI":"10.18632\/oncotarget.6990","volume":"7","author":"Z Fu","year":"2016","unstructured":"Fu, Z. et al. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget 7, 9429 (2016).","journal-title":"Oncotarget"},{"key":"52003_CR18","doi-asserted-by":"publisher","first-page":"852700","DOI":"10.3389\/fimmu.2022.852700","volume":"13","author":"R Li","year":"2022","unstructured":"Li, R. et al. Generation of a high-affinity nanobody against CD147 for tumor targeting and therapeutic efficacy through conjugating doxorubicin. Front. Immunol. 13, 852700 (2022).","journal-title":"Front. Immunol."},{"key":"52003_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/hed.23885","volume":"38","author":"JW Frederick","year":"2016","unstructured":"Frederick, J. W., Sweeny, L., Hartman, Y., Zhou, T. & Rosenthal, E. L. Epidermal growth factor receptor inhibition by anti-CD147 therapy in cutaneous squamous cell carcinoma. Head Neck. 38, 247\u2013252 (2016).","journal-title":"Head Neck"},{"key":"52003_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bbrc.2008.06.122","volume":"374","author":"M Baba","year":"2008","unstructured":"Baba, M., Inoue, M., Itoh, K. & Nishizawa, Y. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem. Biophys. Res. Commun. 374, 111\u2013116 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"52003_CR21","doi-asserted-by":"crossref","unstructured":"He, B. et al. Epitope mapping of metuximab on CD147 using phage display and molecular docking. Comput. Math. Methods Med. 983829 (2013). (2013).","DOI":"10.1155\/2013\/983829"},{"key":"52003_CR22","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.bbrc.2019.04.046","volume":"513","author":"M Huhe","year":"2019","unstructured":"Huhe, M. et al. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer. Biochem. Biophys. Res. Commun. 513, 1083\u20131091 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"52003_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi, D. & Weiner, L. Monoclonal antibodies in cancer therapy. Antibodies 9, 34 (2020).","journal-title":"Antibodies"},{"key":"52003_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41408-024-01050-6","volume":"14","author":"SA Stefa\u0144czyk","year":"2024","unstructured":"Stefa\u0144czyk, S. A. et al. Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody. Blood Cancer J. 14, 67 (2024).","journal-title":"Blood Cancer J."},{"key":"52003_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","volume":"9","author":"CL Arteaga","year":"2012","unstructured":"Arteaga, C. L. et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Onco. 9, 16\u201332 (2012).","journal-title":"Nat. Rev. Clin. Onco"},{"key":"52003_CR26","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","volume":"70","author":"GM Keating","year":"2010","unstructured":"Keating, G. M. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70, 1445\u20131476 (2010).","journal-title":"Drugs"},{"key":"52003_CR27","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s42003-024-06659-8","volume":"7","author":"SW de Taeye","year":"2024","unstructured":"de Taeye, S. W. et al. Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing. Commun. Biol. 7, 964 (2024).","journal-title":"Commun. Biol."},{"key":"52003_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/cancers15010038","volume":"15","author":"MM Alasmari","year":"2022","unstructured":"Alasmari, M. M. A review of margetuximab-based therapies in patients with HER2-positive metastatic breast cancer. Cancers 15, 38 (2022).","journal-title":"Cancers"},{"key":"52003_CR29","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","volume":"115","author":"FT Awan","year":"2010","unstructured":"Awan, F. T. et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115, 1204\u20131213 (2010).","journal-title":"Blood"},{"key":"52003_CR30","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","volume":"18","author":"D Loo","year":"2012","unstructured":"Loo, D. et al. Development of an Fc-enhanced anti\u2013B7-H3 monoclonal antibody with potent antitumor activity. Clin. Cancer Res. 18, 3834\u20133845 (2012).","journal-title":"Clin. Cancer Res."},{"key":"52003_CR31","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.3390\/ijms25126626","volume":"25","author":"T Pamonsupornwichit","year":"2024","unstructured":"Pamonsupornwichit, T. et al. Engineered CD147-deficient THP-1 impairs monocytic myeloid-derived suppressor cell differentiation but maintains antibody-dependent cellular phagocytosis function for Jurkat T-ALL cells with humanized anti-CD147 antibody. Int. J. Mol. Sci. 25, 6626 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"52003_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/antib14020036","volume":"14","author":"K Thongheang","year":"2025","unstructured":"Thongheang, K. et al. Potentiating antibody-dependent cellular cytotoxicity in triple-negative breast cancer via the humanized anti-CD147 antibody. Antibodies 14, 36 (2025).","journal-title":"Antibodies"},{"key":"52003_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-025-04203-z","volume":"74","author":"T Pamonsupornwichit","year":"2025","unstructured":"Pamonsupornwichit, T. et al. Overcoming NK cell resistance in triple-negative breast cancer via adcc with a humanized anti-CD147 antibody. Cancer Immunol. Immunother. 74, 1\u201317 (2025).","journal-title":"Cancer Immunol. Immunother"},{"key":"52003_CR34","doi-asserted-by":"crossref","unstructured":"Xu, J. & Zhu, H. H. Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH annual meeting. Exp. Hematol. Oncol. 12, 30 (2023).","DOI":"10.1186\/s40164-023-00384-4"},{"key":"52003_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1309\/AJCPMF03LVSBLHPJ","volume":"144","author":"MJ You","year":"2015","unstructured":"You, M. J., Medeiros, L. J. & Hsi, E. D. T-lymphoblastic leukemia\/lymphoma. Am. J. Clin. Pathol. 144, 411\u2013422 (2015).","journal-title":"Am. J. Clin. Pathol."},{"key":"52003_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","volume":"8","author":"S Shimony","year":"2024","unstructured":"Shimony, S., DeAngelo, D. J. & Luskin, M. R. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 8, 23\u201336 (2024).","journal-title":"Blood Adv."},{"key":"52003_CR37","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/cancers14081873","volume":"14","author":"E Genesc\u00e0","year":"2022","unstructured":"Genesc\u00e0, E. & la Starza, R. Early T-cell precursor ALL and beyond: immature and ambiguous lineage T-ALL subsets. Cancers 14, 1873 (2022).","journal-title":"Cancers"},{"key":"52003_CR38","doi-asserted-by":"publisher","first-page":"e11374","DOI":"10.1097\/MD.0000000000011374","volume":"97","author":"M Hu","year":"2018","unstructured":"Hu, M. et al. Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation. Medicine 97, e11374 (2018).","journal-title":"Medicine"},{"key":"52003_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/antib14020031","volume":"14","author":"WJ Walton","year":"2025","unstructured":"Walton, W. J. et al. Impact of monoclonal antibody aggregates on effector function characterization. Antibodies 14, 31 (2025).","journal-title":"Antibodies"},{"key":"52003_CR40","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.3390\/cancers12103041","volume":"12","author":"HJ van der Horst","year":"2020","unstructured":"van der Horst, H. J., Nijhof, I. S., Mutis, T. & Chamuleau, M. E. D. Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies. Cancers 12, 3041 (2020).","journal-title":"Cancers"},{"key":"52003_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/antib8040055","volume":"8","author":"ML Chiu","year":"2019","unstructured":"Chiu, M. L., Goulet, D. R., Teplyakov, A. & Gilliland, G. L. Antibody structure and function: the basis for engineering therapeutics. Antibodies 8, 55 (2019).","journal-title":"Antibodies"},{"key":"52003_CR42","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1021\/acschembio.5b01035","volume":"11","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Stabilizing the CH2 domain of an antibody by engineering in an enhanced aromatic sequon. ACS Chem. Biol. 11, 1852\u20131861. https:\/\/doi.org\/10.1021\/acschembio.5b01035 (2016).","journal-title":"ACS Chem. Biol."},{"key":"52003_CR43","doi-asserted-by":"publisher","first-page":"2282250","DOI":"10.1080\/2162402X.2023.2282250","volume":"12","author":"H Wu","year":"2023","unstructured":"Wu, H. et al. A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC. OncoImmunology 12, 2282250. https:\/\/doi.org\/10.1080\/2162402X.2023.2282250 (2023).","journal-title":"OncoImmunology"},{"key":"52003_CR44","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1073\/pnas.0508123103","volume":"103","author":"GA Lazar","year":"2006","unstructured":"Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Nat. Acad. Sci. 103, 4005\u20134010. https:\/\/doi.org\/10.1073\/pnas.0508123103 (2006).","journal-title":"Proc. Nat. Acad. Sci."},{"key":"52003_CR45","doi-asserted-by":"publisher","first-page":"8947","DOI":"10.3390\/ijms22168947","volume":"22","author":"P Gogesch","year":"2021","unstructured":"Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z. & Anzaghe, M. The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies. Int. J. Mol. Sci. 22, 8947 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"52003_CR46","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/antib9040064","volume":"9","author":"R Liu","year":"2020","unstructured":"Liu, R., Oldham, R. J., Teal, E., Beers, S. A. & Cragg, M. S. Fc-engineering for modulated effector functions-improving antibodies for cancer treatment. Antibodies 9, 64 (2020).","journal-title":"Antibodies"},{"key":"52003_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark. Res. 8, 49. https:\/\/doi.org\/10.1186\/s40364-020-00228-x (2020).","journal-title":"Biomark. Res."},{"key":"52003_CR48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/08830180902978120","volume":"28","author":"F Zhou","year":"2009","unstructured":"Zhou, F. Molecular mechanisms of IFN-\u03b3 to up-regulate MHC class I antigen processing and presentation. Int. Rev. Immunol. 28, 239\u2013260. https:\/\/doi.org\/10.1080\/08830180902978120 (2009).","journal-title":"Int. Rev. Immunol."},{"key":"52003_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","volume":"13","author":"H Ikeda","year":"2002","unstructured":"Ikeda, H., Old, L. J. & Schreiber, R. D. The roles of IFN\u03b3 in protection against tumor development and cancer immunoediting. Cytokine Growth Factor. Rev. 13, 95\u2013109. https:\/\/doi.org\/10.1016\/S1359-6101(01)00038-7 (2002).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"52003_CR50","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/19420862.2018.1474996","volume":"10","author":"NS Alakhras","year":"2018","unstructured":"Alakhras, N. S. et al. Fc\u03b3RIIIa-dependent IFN-\u03b3 release in whole blood assay is predictive of therapeutic IgG1 antibodies safety. MAbs 10, 913\u2013921. https:\/\/doi.org\/10.1080\/19420862.2018.1474996 (2018).","journal-title":"MAbs"},{"key":"52003_CR51","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3390\/cancers17060958","volume":"17","author":"I Buyukgolcigezli","year":"2025","unstructured":"Buyukgolcigezli, I., Tenekeci, A. K. & Sahin, I. H. Opportunities and challenges in antibody-drug conjugates for cancer therapy: a new era for cancer treatment. Cancers 17, 958 (2025).","journal-title":"Cancers"},{"key":"52003_CR52","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/cancers13020312","volume":"13","author":"KJ Dixon","year":"2021","unstructured":"Dixon, K. J., Wu, J. & Walcheck, B. Engineering anti-tumor monoclonal antibodies and fc receptors to enhance ADCC by human NK cells. Cancers 13, 312 (2021).","journal-title":"Cancers"},{"key":"52003_CR53","first-page":"1","volume":"51","author":"TH Kang","year":"2019","unstructured":"Kang, T. H. & Jung, S. T. Boosting therapeutic potency of antibodies by taming Fc domain functions. Exp. Mol. Med. 51, 1\u20139 (2019).","journal-title":"Exp. Mol. Med."},{"key":"52003_CR54","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/jcp.2007.051144","volume":"61","author":"JD Edgar","year":"2008","unstructured":"Edgar, J. D. T cell immunodeficiency. Clin. Pathol. 61, 988\u2013993 (2008).","journal-title":"Clin. Pathol."},{"key":"52003_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13287-021-02277-x","volume":"12","author":"MG Lamb","year":"2021","unstructured":"Lamb, M. G., Rangarajan, H. G., Tullius, B. P. & Lee, D. A. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell. Res. Ther. 12, 211 (2021).","journal-title":"Stem Cell. Res. Ther."},{"key":"52003_CR56","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.3390\/ijms24119521","volume":"24","author":"F Portale","year":"2023","unstructured":"Portale, F. & Di Mitri, D. NK cells in cancer: mechanisms of dysfunction and therapeutic potential. Int. J. Mol. Sci. 24, 9521 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"52003_CR57","doi-asserted-by":"publisher","first-page":"17411","DOI":"10.3390\/ijms151017411","volume":"15","author":"L Xiong","year":"2014","unstructured":"Xiong, L., Edwards, C. K. III & Zhou, L. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int. J. Mol. Sci. 15, 17411\u201317441 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"52003_CR58","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41392-021-00603-6","volume":"6","author":"H Bian","year":"2021","unstructured":"Bian, H. et al. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial. Signal. Transduct. Target. Ther. 6, 194 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"52003_CR59","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/acs.molpharmaceut.2c00954","volume":"20","author":"J Ye","year":"2023","unstructured":"Ye, J. et al. Safety, biodistribution, and dosimetry study of meplazumab, a potential COVID-19 therapeutic drug, with 131I-labeling and SPECT imaging. Mol. Pharm. 20, 1750\u20131757 (2023).","journal-title":"Mol. Pharm."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52003-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52003-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52003-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:03:16Z","timestamp":1783476196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52003-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52003"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52003-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted with approval from the Ethics Committee, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand (AMSEC-68EX-034).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"21141"}}